List of Zerviate drug patents

Zerviate is owned by Eyevance.

Zerviate contains Cetirizine Hydrochloride.

Zerviate has a total of 6 drug patents out of which 0 drug patents have expired.

Zerviate was authorised for market use on 30 May, 2017.

Zerviate is available in solution/drops;ophthalmic dosage forms.

Zerviate can be used as treatment of ocular itching associated with allergic conjunctivitis.

The generics of Zerviate are possible to be released after 09 January, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9993471 EYEVANCE Ophthalmic formulations of cetirizine and methods of use
Mar, 2030

(7 years from now)

US8829005 EYEVANCE Ophthalmic formulations of cetirizine and methods of use
Mar, 2030

(7 years from now)

US9750684 EYEVANCE Ophthalmic formulations of cetirizine and methods of use
Mar, 2030

(7 years from now)

US8829005

(Pediatric)

EYEVANCE Ophthalmic formulations of cetirizine and methods of use
Sep, 2030

(7 years from now)

US9254286 EYEVANCE Ophthalmic formulations of cetirizine and methods of use
Jul, 2032

(9 years from now)

US9254286

(Pediatric)

EYEVANCE Ophthalmic formulations of cetirizine and methods of use
Jan, 2033

(9 years from now)

Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 May, 2017

Treatment: Treatment of ocular itching associated with allergic conjunctivitis

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in